Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 6/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.36 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL567354 | 0.91 | ADRA1D (0.40) | HTR1AADRA1DADRA1AADRA1BMAPT | |
| SCHEMBL8192039 | 0.80 | HTR1A (0.46) | HTR1AADRA1DADRA1AADRA1BMAPT | |
| SCHEMBL15865422 | 0.80 | PYGL (0.38) | FFAR1RECQLPOLB | |
| SCHEMBL15865418 | 0.80 | PYGL (0.38) | FFAR1RECQLPOLB | |
| SCHEMBL15865484 | 0.78 | MAOB (0.52) | FFAR1 | |
| SCHEMBL567322 | 0.78 | MAOB (0.52) | FFAR1 | |
| SCHEMBL567621 | 0.78 | MAOB (0.52) | FFAR1 | |
| SCHEMBL1545420 | 0.77 | CA2 (0.55) | MAPK1L3MBTL1CA2RECQLTSHR | |
| SCHEMBL7982000 | 0.77 | CA2 (0.55) | MAPK1L3MBTL1CA2RECQLTSHR | |
| SCHEMBL2544576 | 0.77 | CA2 (0.55) | MAPK1L3MBTL1CA2RECQLTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035210-A9 | 2,3-DIHYDROBENZO(1,4) DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEME DISEASES | ORION CORPORATION (FI) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035210-A9 | 2,3-DIHYDROBENZO(1,4) DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEME DISEASES | PMP22, NPY2R, ADRA2C | HTR1A 207/4885ADRA1D 135/4885ADRA1A 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.